Engineered immune cells take on tough leukemia in early trial
NCT ID NCT07668557
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tests a new treatment called ICG415 CAR-T cells for adults with acute myeloid leukemia that has come back or not responded to standard therapy. The treatment involves taking a patient's own immune cells, engineering them to recognize and attack leukemia cells, and infusing them back after a short chemotherapy course. The main goals are to check safety and see if the treatment can shrink the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ICG415 CAR-T cells (engineered immune cells targeting CD33 and CLL1 proteins on leukemia cells)
What this could lead to
If successful, this could point toward a new treatment option for patients with hard-to-treat acute myeloid leukemia.
What could go wrong
This is a very early, small Phase 1 trial focused on safety, not proof of effectiveness. CAR-T therapy can cause severe side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangxi Provincial People's Hospital (Participating Site)
RECRUITINGNanchang, Jiangxi, 330006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Nanchang University (Lead Site)
RECRUITINGNanchang, Jiangxi, 330006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••